Literature DB >> 33466236

The Network of Cytokines in Brain Metastases.

Jawad Fares1, Alex Cordero1, Deepak Kanojia1, Maciej S Lesniak1.   

Abstract

Brain metastases are the most common of all intracranial tumors and a major cause of death in patients with cancer. Cytokines, including chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors are key regulators in the formation of brain metastases. They regulate the infiltration of different cellular subsets into the tumor microenvironment and affect the therapeutic outcomes in patients. Elucidating the cancer cell-cytokine interactions in the setting of brain metastases is crucial for the development of more accurate diagnostics and efficacious therapies. In this review, we focus on cytokines that are found in the tumor microenvironment of brain metastases and elaborate on their trends of expression, regulation, and roles in cellular recruitment and tumorigenesis. We also explore how cytokines can alter the anti-tumor response in the context of brain metastases and discuss ways through which cytokine networks can be manipulated for diagnosis and treatment.

Entities:  

Keywords:  brain metastasis; brain tumor; chemokines; cytokines; interferons; interleukins; lymphokines; tumor necrosis factors

Year:  2021        PMID: 33466236      PMCID: PMC7795138          DOI: 10.3390/cancers13010142

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  123 in total

1.  High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma.

Authors:  Min Ho Park; Ji Shin Lee; Jung Han Yoon
Journal:  J Surg Oncol       Date:  2012-03-15       Impact factor: 3.454

2.  High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma.

Authors:  Benjamin Weide; Tina Schäfer; Alexander Martens; Anastasia Kuzkina; Laura Uder; Seema Noor; Claus Garbe; Patrick N Harter; Michel Mittelbronn; Jörg Wischhusen
Journal:  J Invest Dermatol       Date:  2016-10-02       Impact factor: 8.551

3.  Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

Authors:  Ahmad A Tarhini; John Cherian; Stergios J Moschos; Hussein A Tawbi; Yongli Shuai; William E Gooding; Cindy Sander; John M Kirkwood
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

Review 4.  Chemokines in cancer.

Authors:  Melvyn T Chow; Andrew D Luster
Journal:  Cancer Immunol Res       Date:  2014-12       Impact factor: 11.151

5.  Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression.

Authors:  Eric V Yang; Seung-jae Kim; Elise L Donovan; Min Chen; Amy C Gross; Jeanette I Webster Marketon; Sanford H Barsky; Ronald Glaser
Journal:  Brain Behav Immun       Date:  2008-10-21       Impact factor: 7.217

6.  Differential chemokine, chemokine receptor, cytokine and cytokine receptor expression in pulmonary adenocarcinoma: diffuse down-regulation is associated with immune evasion and brain metastasis.

Authors:  Koichi Ohshima; Makoto Hamasaki; Yoshifumi Makimoto; Satoshi Yoneda; Akira Fujii; Yasushi Takamatsu; Manabu Nakashima; Takeshi Watanabe; Katunobu Kawahara; Masahiro Kikuchi; Takayuki Shirakusa
Journal:  Int J Oncol       Date:  2003-10       Impact factor: 5.650

7.  KiSS1-induced GPR54 signaling inhibits breast cancer cell migration and epithelial-mesenchymal transition via protein kinase D1.

Authors:  K Tan; S-G Cho; W Luo; T Yi; X Wu; S Siwko; M Liu; W Yuan
Journal:  Curr Mol Med       Date:  2014       Impact factor: 2.222

8.  Brain metabolomic profiles of lung cancer patients prior to treatment characterized by proton magnetic resonance spectroscopy.

Authors:  Helene Benveniste; Shaonan Zhang; Ruth A Reinsel; Haifang Li; Hedok Lee; Mario Rebecchi; William Moore; Christoffer Johansen; Douglas L Rothman; Thomas V Bilfinger
Journal:  Int J Clin Exp Med       Date:  2012-04-06

9.  Current state of clinical trials in breast cancer brain metastases.

Authors:  Jawad Fares; Deepak Kanojia; Alex Cordero; Aida Rashidi; Jason Miska; Charles W Schwartz; Solomiia Savchuk; Atique U Ahmed; Irina V Balyasnikova; Massimo Cristofanilli; William J Gradishar; Maciej S Lesniak
Journal:  Neurooncol Pract       Date:  2019-02-11

10.  An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation.

Authors:  Xiaoyan Liu; Hong Fang; Hongchao Chen; Xiaoling Jiang; Deren Fang; Yan Wang; Dingxian Zhu
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

View more
  6 in total

1.  Single-Cell Proteomics Analysis of Recurrent Low-Grade Serous Ovarian Carcinoma and Associated Brain Metastases.

Authors:  Tanja Pejovic; Pierre-Valérien Abate; Hongli Ma; Jaclyn Thiessen; Christopher L Corless; Abigail Peterson; Hugues Allard-Chamard; Marilyne Labrie
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

Review 2.  Emerging principles of brain immunology and immune checkpoint blockade in brain metastases.

Authors:  Jawad Fares; Ilya Ulasov; Peter Timashev; Maciej S Lesniak
Journal:  Brain       Date:  2021-05-07       Impact factor: 13.501

3.  Transcription Profile and Pathway Analysis of the Endocannabinoid Receptor Inverse Agonist AM630 in the Core and Infiltrative Boundary of Human Glioblastoma Cells.

Authors:  Gareth Williams; David Chambers; Ruman Rahman; Francisco Molina-Holgado
Journal:  Molecules       Date:  2022-03-22       Impact factor: 4.411

4.  Effects of Serum From Radiofrequency Ablation Patients Receiving General Anesthesia or Local Anesthesia on Hepatocellular Carcinoma Cancer Cell Malignancy: A Prospective Randomized Controlled Trial.

Authors:  Yumiao Shi; Tong Wu; Tao Wang; Yan Liu; Xiaoqiang Wang; Jiamei Luo; Diansan Su; Bo Zhai; Jie Tian
Journal:  Front Oncol       Date:  2021-09-23       Impact factor: 6.244

5.  MCP-1/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression.

Authors:  Sabina Pozzi; Anna Scomparin; Dikla Ben-Shushan; Eilam Yeini; Paula Ofek; Alessio D Nahmad; Shelly Soffer; Ariel Ionescu; Antonella Ruggiero; Adi Barzel; Henry Brem; Thomas M Hyde; Iris Barshack; Sanju Sinha; Eytan Ruppin; Tomer Weiss; Asaf Madi; Eran Perlson; Inna Slutsky; Helena F Florindo; Ronit Satchi-Fainaro
Journal:  JCI Insight       Date:  2022-09-08

6.  Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers.

Authors:  Jarushka Naidoo; Karisa C Schreck; Wei Fu; Chen Hu; Alexander Carvajal-Gonzalez; Roisin M Connolly; Cesar A Santa-Maria; Evan J Lipson; Matthias Holdhoff; Patrick M Forde; Christopher Douville; Joanne Riemer; Amanda Barnes; Kristin J Redmond; Lawrence Kleinberg; Brandi Page; Nafi Aygun; Kenneth W Kinzler; Nickolas Papadopoulos; Chetan Bettegowda; Arun Venkatesan; Julie R Brahmer; Stuart A Grossman
Journal:  J Immunother Cancer       Date:  2021-08       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.